Angiotensin II-induced hypertension enhanced therapeutic efficacy of liposomal doxorubicin in tumor-bearing mice.

Abstract

In this study, we investigated whether the therapeutic efficacy of liposomal doxorubicin (DXR-SL) could be enhanced by angiotensin II (AT)-induced hypertension. AT-induced hypertension increased the volume of tumor blood flow in mice bearing a poorly vascularized Lewis lung carcinoma (LLC) tumor, but only slightly in mice bearing a well-vascularized colon carcinoma Colon 26 (C26) tumor. In therapeutic efficacy, AT-induced hypertension enhanced the antitumor activity of DXR-SL in mice bearing LLC and C26 tumors. Localization of DXR-SL after injection by AT-induced hypertension was observed outside tumor blood vessels in LLC and C26 tumors, but within them under the normotension. From these findings, AT-induced hypertension had potential to improve the delivery of DXR-SL to both well- and poorly vascularized solid tumors.

• Authors: Yoshiyuki Hattori, Haruya Ubukata, Kumi Kawano, Yoshie Maitani
• Journal: International journal of pharmaceutics (Int J Pharm) Vol. 403 Issue 1-2 Pg. 178-84 (Jan 17 2011) ISSN: 1873-3476 [Electronic] Netherlands
• PMID: 20934498 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2010 Elsevier B.V. All rights reserved.

Chemical References

• Antibiotics, Antineoplastic
• Liposomes
• Angiotensin II
• Doxorubicin

Topics

• Angiotensin II (administration & dosage)
• Animals
• Antibiotics, Antineoplastic (administration & dosage, pharmacokinetics, therapeutic use)
• Blood Circulation
• Carcinoma, Lewis Lung (blood supply, drug therapy)
• Colonic Neoplasms (blood supply, drug therapy)
• Doxorubicin (administration & dosage, pharmacokinetics, therapeutic use)
• Female
• Hypertension (chemically induced, physiopathology)
• Injections, Intravenous
• Liposomes
• Mice
• Mice, Inbred Strains
• Tissue Distribution